Janssen Research & Development
GPTKB entity
Properties (53)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
gptkb:Johnson_&_Johnson
|
| gptkbp:awards |
Best Places to Work
Top Employer |
| gptkbp:clinicalTrials |
Phase 1
global reach Phase 2 Phase 3 patient-centric approach Phase 4 |
| gptkbp:collaboratesWith |
academic institutions
biotech companies |
| gptkbp:communityPrograms |
health education
patient support disease awareness |
| gptkbp:employees |
over 10,000
|
| gptkbp:focus |
biopharmaceuticals
|
| gptkbp:founded |
2002
|
| gptkbp:headquarters |
gptkb:Beerse,_Belgium
|
| https://www.w3.org/2000/01/rdf-schema#label |
Janssen Research & Development
|
| gptkbp:innovation |
gene therapy
biologics cell therapy drug_discovery |
| gptkbp:leadership |
scientific experts
research scientists industry veterans clinical trial specialists |
| gptkbp:operatesIn |
global market
|
| gptkbp:parentCompany |
gptkb:Johnson_&_Johnson
|
| gptkbp:partnerships |
gptkb:CEPI
NGOs WHO GAVI |
| gptkbp:products |
gptkb:Xarelto
gptkb:Tremfya gptkb:Invega Stelara Darzalex |
| gptkbp:research |
millions annually
|
| gptkbp:researchAreas |
oncology
neuroscience cardiovascular diseases infectious diseases immunology |
| gptkbp:subsidiary |
gptkb:Janssen_Vaccines
gptkb:Janssen_Biotech gptkb:Janssen_Pharmaceuticals |
| gptkbp:sustainabilityInitiatives |
community engagement
diversity and inclusion environmental responsibility healthcare_access |
| gptkbp:website |
www.janssen.com
|